Takashi Shimada

Part of PhoenixBio Co., Ltd., PhoenixBio USA Corp. develops technologies for mass propagation of human cells into laboratory animals. The private company is based in New York, NY. Yoshio Morikawa has been the CEO of the company since 2015.

KMT Hepatech, Inc. provides vivo research services focusing on preclinical development of Hepatitis C, Hepatitis B, and Malaria therapeutics and vaccines. It offers scientific evaluation services for drug metabolism, lipoprotein metabolism, dose response, and drug treatment. The firm provides KMT Mouse, a transgenic mouse model for practical testing of HCV drug candidates. The company was founded by Norman Miles Kneteman, David F. Mercer and David Lorne John Tyrrell in 2001 and is headquartered in Edmonton, Canada.

Institute of Immunology Co., Ltd. engages in the manufacture and sale of diagnostic reagents and monoclonal antibodies for research purpose. It develops and produces Enzyme Immunoassay (EIA) kits related to infectious diseases such as hepatitis B as well as those for human hepatocellular growth factor determination. The firm also offers EIA kits for detecting hepatitis E virus antibody and for determining the genotypes of hepatitis B virus and offers immunization of 3 mice, evaluation, fusion, screening, cloning, ascites production and purification services to the research, clinical and medical industries. The company was founded by Tetsuo Nakamura on August 18, 1979 and is headquartered in Tokyo, Japan.